GlassScriptPhysician profile
Jody Leonard
NPI 1679041123
$7,188.68
in general payments reported to CMS, 2019-2025
35 companies · $1,386 in 2025
The $1,386 reported for 2025 was more than what 91% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,558 · 2022: $909 · 2023: $1,200 · 2024: $1,135 · 2025: $1,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,653 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,653.07 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,161.88 | 2021-2024 | Axonics |
| Sumitomo Pharma America, INC. | $818.97 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $540.36 | 2022-2025 | |
| Janssen Biotech, INC. | $436.05 | 2022-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $385.10 | 2022-2025 | Myrbetriq, Xtandi |
| Ferring Pharmaceuticals INC. | $368.24 | 2024-2025 | Adstiladrin |
| Urovant Sciences INC | $337.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $242.25 | 2023-2025 | |
| Dendreon Pharmaceuticals LLC | $186.84 | 2021-2025 | Provenge |
| Endo Pharmaceuticals INC. | $183.80 | 2021-2023 | Aveed, Xiaflex |
| Teleflex LLC | $149.63 | 2021-2024 | Solesta |
| Abbvie INC. | $142.99 | 2023-2025 | |
| Pfizer INC. | $139.17 | 2024-2025 | |
| Novo Nordisk INC | $134.47 | 2021 | |
| Accord Healthcare, INC. | $128.28 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $101.26 | 2023-2025 | Eligard, Jatenzo |
| Coloplast Corp | $86.75 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $72.74 | 2021-2022 | |
| Urogen Pharma, INC. | $71.01 | 2025 | |
| Merck Sharp & Dohme LLC | $69.20 | 2021-2025 | Keytruda, Keytruda Qlex |
| Philips North America LLC | $50.21 | 2025 | Disease Management Solutions Equipment Undivided |
| Astrazeneca Pharmaceuticals LP | $47.08 | 2024-2025 | Lynparza |
| Olympus America INC. | $41.24 | 2023 | Itind System |
| Glaxosmithkline, LLC. | $41.11 | 2022-2023 | Boostrix, Shingrix |
| Bioprotect Medical, INC. | $38.98 | 2025 | Bioprotect Balloon Implant System |
| Myovant Sciences INC. | $37.54 | 2021-2022 | |
| Endo USA, INC. | $33.47 | 2024-2025 | Aveed, Xiaflex |
| Valencia Technologies Corporation | $25.74 | 2023 | Ecoin Device Kit |
| Blue Earth Diagnostics | $21.19 | 2021 | |
| Progenics Pharmaceuticals, INC. | $19.72 | 2024 | |
| Telix Pharmaceuticals | $17.53 | 2023 | Illuccix |
| Sun Pharmaceutical Industries INC. | $17.34 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $15.76 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $14.86 | 2023 | Imbruvica |
| Clovis Oncology, INC. | $10.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Leonard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.